Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters

Management of patients with cutaneous melanoma in the absence of lymph node metastases is still controversial. The experience at the National Cancer Institute in Naples was analyzed to evaluate 3-year disease-free survival and overall survival for all patients who underwent sentinel lymph node biops...

Full description

Saved in:
Bibliographic Details
Published in:Annals of surgical oncology 2004-03, Vol.11 (3 Suppl), p.198S-202S
Main Authors: Caracò, Corrado, Celentano, Egidio, Lastoria, Secondo, Botti, Gerardo, Ascierto, Paolo Antonio, Mozzillo, Nicola
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Child
Disease-Free Survival
Female
Humans
Lymphatic Metastasis
Male
Melanoma - mortality
Melanoma - pathology
Middle Aged
Prognosis
Retrospective Studies
Sentinel Lymph Node Biopsy
Skin Neoplasms - mortality
Skin Neoplasms - pathology
Skin Neoplasms - secondary
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Management of patients with cutaneous melanoma in the absence of lymph node metastases is still controversial. The experience at the National Cancer Institute in Naples was analyzed to evaluate 3-year disease-free survival and overall survival for all patients who underwent sentinel lymph node biopsy (SLB) with Breslow thickness greater than 4 mm. Data from 359 sentinel biopsies performed in the past 5 years were reviewed to determine the effect of the treatment on disease-free survival and overall survival after stratifying patients for node status, tumor ulceration, and Breslow thickness. Statistical analysis showed a better 3-year survival for sentinel node-negative patients than for sentinel node-positive cases (88.4% and 72.9%, respectively; P
ISSN:1068-9265
1534-4681
DOI:10.1245/ASO.2004.12.921